Acebutolol

Research use only, not for human use.

A cardioselective beta blocker for the treatment of hypertension and arrhythmias.

A cardioselective beta blocker for the treatment of hypertension and arrhythmias.Hypertension Approved.

——

Acebutolol is a beta blocker for the treatment of hypertension and arrhythmias. Acebutolol following single intravenous administration (10 mg/kg) to rat results in the plasma clearance of 61.9 mL/min/kg, the volume of distribution of 9.6 L/kg, and an elimination half-life of 1.8 hours. Acebutolol following single intravenous administration (50 mg/kg) to rat results in the plasma clearance of 46.5 mL/min/kg, the volume of distribution of 9.5 L/kg, and an elimination half-life of 2.3 hours.Acebutolol (30 mg/kg) decreases cardiac output by 65% and 31% after 1 min and 10 min measurements, respectively, in Sprague-Dawley rats. Acebutolol (30 mg/kg) significantly reduces regional blood flow (RBF) in most organs either after 1 min or 10 min measurements when compare with the baseline values in Sprague-Dawley rats.

Acebutolol | Acetobutolol | Neptal | Prent | Sectral | Dl-Acebutolol

GPCR/G Protein

Adrenergic Receptor

Adrenergic Receptor

Cardiovascular Disease

Hypertension

37517-30-9

336.426

C18H28N2O4

>98% (HPLC)

——

CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C

N-[3-Acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]butanamide

(-20℃)

With Ice Pack

≥ 2 years